average weight loss with glp-1 agonists Drugs Market Report, 2025-2030 GLP-1 Medications for Weight Loss:

Patients were randomized 1:1 to receive subcutaneous semaglutide 2.4 mg once weekly or placebo as an adjunct to standard-of-care therapy for CVD, such as cholesterol-modifying medications, antiplatelet therapies and antihypertensive agents

Some people experience no gastrointestinal issues with tirzepatide but cannot tolerate semaglutide, or vice versa

Nunn, E

Its important to note that just four days ago, a paper in the American Journal of Ophthalmology found that there was no significant increase in risk of NAION or (ischemic optic neuropathy) in patients taking semaglutide or GLP-1 drugs compared to control group patients with Type 2 diabetes or high BMI